Novo Nordisk vs. Regeneron Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?

Regeneron is presented as the preferred 2026 investment over Novo Nordisk after FY2025 revenue of $14.3B (+1%) and net income of $4.5B, supported by record sales across Dupixent, EYLEA HD and Libtayo and a wide earnings beat. Regeneron also has stronger balance-sheet liquidity, with a 0.1x debt-to-equity ratio and 4.1x current ratio, versus Novo's 0.7x and 0.8x, respectively. Novo generated $47.7B in FY2025 revenue (+6.4%) and $15.8B in net income, but faces GLP-1 pricing pressure, potential U.S. coverage reductions and intensified competition from Eli Lilly. Valuation favors Novo at 12.5x forward P/E versus Regeneron's 14.3x, although the article views Regeneron's diversified growth profile as more attractive.

Analysis

The apparent valuation discount in NVO is not automatically attractive: GLP-1 pricing pressure flows almost directly to earnings because obesity-care fixed costs and manufacturing investment are already embedded. LLY is the cleaner relative beneficiary if U.S. reimbursement becomes more restrictive, since payers can use its product as a credible negotiating alternative; the key issue is net price and formulary access rather than prescription-volume headlines. Over the next 1-3 months, U.S. commercial coverage decisions and any federal obesity-drug reimbursement change are more likely to drive NVO's multiple than incremental demand data.

REGN's superior balance-sheet flexibility gives it an underappreciated option on business development and internal pipeline investment while peers face higher financing costs. However, its earnings quality should not be treated as diversified simply because several products are growing: EYLEA conversion to HD must outrun biosimilar-driven erosion of the legacy franchise, while Dupixent economics remain partly dependent on SNY collaboration terms. The relevant 6-18 month catalyst path is therefore EYLEA HD share retention, Dupixent indication expansion and pipeline readouts—not a broad healthcare multiple rerating.

The contrarian setup is that the article's pro-REGN conclusion may already reflect recent operating momentum, whereas NVO's compressed valuation could be pricing a more severe and durable GLP-1 price reset than ultimately occurs. A stabilization in NVO net pricing, oral-obesity uptake, or supply availability would produce meaningful operating leverage and multiple recovery. Conversely, any cut to obesity guidance driven by realized rebates or formulary exclusions would confirm that the lower multiple is deserved.

This is not a high-conviction standalone news trade without current consensus estimates, net-price trends, EYLEA HD prescription-share data, and positioning. The more robust expression is relative: REGN offers lower balance-sheet risk, while NVO remains the higher-beta policy and competitive-dislocation vehicle.

Key Decisions for Investors

• Initiate a 3-6 month market-neutral pair: long REGN / short NVO in equal dollar amounts only after confirming REGN consensus EPS has not already moved materially higher following its latest results. Target 10-15% relative outperformance; exit if EYLEA HD conversion stalls for two consecutive monthly prescription datasets or if NVO raises guidance on improved realized pricing.
• Maintain LLY as the preferred long GLP-1 exposure versus NVO through the next U.S. payer/formulary cycle. Add only on evidence that LLY is gaining covered lives without a proportional deterioration in realized net price; the thesis is falsified if NVO preserves formulary access while LLY's rebate intensity accelerates.
• Do not add outright REGN on the collaboration narrative alone. Set an alert around the next earnings release for legacy EYLEA decline, EYLEA HD mix, Dupixent royalty/collaboration contribution, and 2027 operating-expense guidance; a legacy-franchise miss paired with higher R&D spend would challenge the expected earnings durability.
• For a contrarian NVO position, wait for independently verifiable stabilization in U.S. obesity net price and revised reimbursement visibility. A 6-12 month long becomes attractive if management can hold or lift earnings guidance despite pricing concessions; avoid if guidance is reduced primarily for U.S. gross-to-net pressure rather than temporary supply costs.